{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:59:27Z","timestamp":1784959167779,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10620-025-08950-y","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T07:37:51Z","timestamp":1741246671000},"page":"1864-1872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center"],"prefix":"10.1007","volume":"70","author":[{"given":"Jo\u00eblle","family":"St-Pierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Fear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushila R.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Pekow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krugliak Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"8950_CR1","doi-asserted-by":"publisher","unstructured":"Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357\u20131373. Available at: https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.018.","DOI":"10.1016\/j.mayocp.2019.01.018"},{"key":"8950_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG clinical guideline: Ulcerative colitis in adults. American Journal of Gastroenterology. 2019;114:384\u2013413.","journal-title":"American Journal of Gastroenterology."},{"key":"8950_CR3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u20131583.","journal-title":"Gastroenterology."},{"key":"8950_CR4","doi-asserted-by":"crossref","unstructured":"McDonald BD, Dyer EC, Rubin DT. IL-23 Monoclonal antibodies for IBD: So many, So different? J Crohns Colitis. 2022;16:II42\u2013II53.","DOI":"10.1093\/ecco-jcc\/jjac038"},{"key":"8950_CR5","doi-asserted-by":"crossref","unstructured":"Gottlieb ZS, Sands BE. Personalised medicine with IL-23 blockers: Myth or reality? J Crohns Colitis. 2022;16:II73\u2013II94.","DOI":"10.1093\/ecco-jcc\/jjab190"},{"key":"8950_CR6","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2023;388:2444\u20132455.","journal-title":"New England Journal of Medicine."},{"key":"8950_CR7","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158:537\u2013549.e10. Available at: https:\/\/doi.org\/10.1053\/j.gastro.2019.08.043.","DOI":"10.1053\/j.gastro.2019.08.043"},{"key":"8950_CR8","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clinical Gastroenterology and Hepatology. 2022;20:105\u2013115.e14. Available at: https:\/\/doi.org\/10.1016\/j.cgh.2020.09.028.","DOI":"10.1016\/j.cgh.2020.09.028"},{"key":"8950_CR9","first-page":"1","volume":"360","author":"MC Dubinsky","year":"2023","unstructured":"Dubinsky MC, Clemow DB, Hunter Gibble T et al. Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission. Crohns Colitis 2023;360:1\u201313.","journal-title":"Crohns Colitis"},{"key":"8950_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","volume":"17","author":"F Magro","year":"2023","unstructured":"Magro F, Pai RK, Kobayashi T et al. Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programmes. J Crohns Colitis. 2023;17:1457\u20131470.","journal-title":"J Crohns Colitis."},{"key":"8950_CR11","unstructured":"Anon. Eli Lilly and Company, OMVOH (mirikizumab-mrkz) [package insert]. U.S. Food and Drug Administration. 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761279s000lbl.pdf [Accessed July 27, 2024]."},{"key":"8950_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang AG et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175\u2013191.","journal-title":"Behav Res Methods."},{"key":"8950_CR13","doi-asserted-by":"crossref","unstructured":"Dubinsky MC, Jairath V, Feagan BG, et al. Changes in health- related quality of life and associations with improvements in clinical efficacy\u202f: a Phase 2 study of mirikizumab in patients with ulcerative colitis. 2023;17:1\u201311.","DOI":"10.1136\/bmjgast-2023-001115"},{"key":"8950_CR14","first-page":"1","volume":"360","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Panaccione R, Lewis JD et al. Impact of bowel urgency on quality of life and clinical outcomes in patients with ulcerative colitis. Crohns Colitis 2022;360:1\u201311.","journal-title":"Crohns Colitis"},{"key":"8950_CR15","first-page":"1","volume":"360","author":"MD Long","year":"2024","unstructured":"Long MD, Schreiber S, Hibi T et al. Association of bowel urgency with quality-of-life measures in patients with moderately-to-severely active ulcerative colitis: results from phase 3 LUCENT-1 (induction) and LUCENT-2 (maintenance) studies. Crohns Colitis 2024;360:1\u201312.","journal-title":"Crohns Colitis"},{"key":"8950_CR16","first-page":"1","volume":"360","author":"BE Sands","year":"2023","unstructured":"Sands BE, Feagan BG, Gibble TH et al. Mirikizumab improves quality of life in patients with moderately-to-severely active ulcerative colitis: results from the phase 3 LUCENT-1 induction and LUCENT-2 maintenance studies. Crohns Colitis 2023;360:1\u201310.","journal-title":"Crohns Colitis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-08950-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:03:57Z","timestamp":1748581437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-08950-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["8950"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-08950-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"5 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.S-P., E.F., A.M., N.K.Choi report no relevant disclosures. D.C. has served on the speaker bureau for Janssen Pharmaceuticals, Eli Lilly and has served as a consultant to Bristol Myers Squibb, and Boehringer Ingelheim, Abbvie, Janssen Pharmaceuticals R.D.C. has served on the speaker bureau for Abbvie and BMC\/Celgene, has served as a consultant to Abbvie Laboratories, Bausch Health, BMC\/Celgene, Eli Lilly, Genentech, Gilead Sciences, Janssen, Pfizer, Takeda, has served on data safety monitoring board of Reistone Biopharma. Clinical trials \/ Grants: Abbviw, BMS\/Celgene, Boehringer Ingelheim, Crohn\u2019s & Colitis foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventism Schwartz Pharma, Seres Therapeutics, Takeda Pharma, UCB Pharma. S.R.D. has served as a consultant for Pfizer; and on the speakers bureau for AbbVie. J.P. has received grant support from AbbVie and Takeda; and has served as a consultant for Veraste and CVS Caremark; and on the advisory board for Takeda, Janssen, and Pfzer. N.K.Cleveland has served as a consultant for NeuroLogica (a subsidiary of Samsung Electronics) and Takeda, and has served as a speaker for Bristol Myers Squibb. D.T.R. has received grant support from Takeda; and has served as a consultant for Abbvie, Altrubio, Abivax SA, Altrubio, Avalo Therapeutics, Bausch Health, Bristol-Myers Squibb, Buhlmann Diagnostics Corp, ClostraBio, Connect BioPharma, Douglas Pharmaceuticals, Eli Lilly & Co., Genentech Inc., InDex Pharmaceuticals, Iterative Health, Janssen Pharmaceuticals, Odyssey Therapeutics, Pfizer, Sanofi and Takeda Pharmaceuticals. He serves on the Board of Trustees for the Crohn\u2019s & Colitis Foundation and is on the Board of Directors for Cornerstones Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the Institutional Review Board (IRB, Ethics Board) at the University of Chicago. Each subject provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}